Pendapatan dodolan perusahaan ars-pharma.com (SPRY)

The GURU.Markets platform displays the corporate sales dynamics of ARS Pharmaceuticals (SPRY), where 0.12 represents the latest level value. The company's growth is driven by innovations in Neffy, a needle-free allergy spray. Demand for the drug is non-cyclical, although it depends on seasonal blooming. Patent protection and FDA approval create a powerful barrier to the emergence of generics.

ARS Corp (SPRY): Pendapatan perusahaan saka 28.04.2023 nganti 13.11.2026

Rincian analitis perusahaan ARS Pharmaceuticals, Inc. (SPRY)

- rega pasar lan target rega analis:

Rega bursa ARS Corp|SPRY - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar ARS Pharmaceuticals, Inc.|SPRY - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham ARS Pharmaceuticals|SPRY - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku ars-pharma.com|SPRY - Aset Agregat Perusahaan

- informasi babagan utang lan solvabilitas:

Koefisien Total Utang marang Modal ARS Pharmaceuticals|SPRY - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal ARS Pharmaceuticals Inc|SPRY - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc.|SPRY - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan ARS Pharmaceuticals|Rasio cepet ars-pharma.com

- data bathi resik lan rasio valuasi:

SPRY - Bathi resik perusahaan|Penghasilan resik sing dikarepake ARS Pharmaceuticals|SPRY - Rasio rega marang bathi|Prakiraan rega marang bathi ars-pharma.com|SPRY - Pangali PEG|Pangali EV/EBITDA ARS Pharmaceuticals, Inc.|SPRY - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan ARS Pharmaceuticals|SPRY - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan ars-pharma.com|SPRY - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep ARS Pharmaceuticals

- indikator volume dodolan lan pendapatan:

SPRY - Dodolan perusahaan|Prakiraan volume pendapatan perusahaan ARS Corp|SPRY - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake ARS Pharmaceuticals, Inc.

Analisis komprehensif perusahaan:ARS Corp (SPRY)

Produk asil prodhuksi ARS Pharmaceuticals Inc

Patent protection for ARS Pharmaceuticals (SPRY) nasal sprays and their integration into medical protocols minimize competition. The company's gross sales volume captures daily cash revenue from these products, stripping the data of market volatility. This indicator's trend reflects real market demand and the commercial efficiency of the business model. Steady growth in these metrics indicates high asset resilience, which reduces risk and justifies the long-term cost of capital.

Pesaing wigati